Management of Adverse Events Associated With Tyrosine Kinase Inhibitor Use in Adult Patients With Chronic Myeloid Leukemia in Chronic Phase: An Advanced Practice Perspective

The tyrosine kinase inhibitors (TKIs) imatinib, dasatinib, nilotinib, bosutinib, and ponatinib have drastically improved the life expectancies of patients with chronic myeloid leukemia in chronic phase (CML-CP). While survival outcomes are comparable across first-line TKIs, each TKI has a unique tox...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Stephanie, Comer, Holly, Ramsey, Brooke, Thomas, Katy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2021
Materias:
Grand Rounds
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299797/
https://www.ncbi.nlm.nih.gov/pubmed/34430062
http://dx.doi.org/10.6004/jadpro.2021.12.5.7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299797/
https://www.ncbi.nlm.nih.gov/pubmed/34430062
http://dx.doi.org/10.6004/jadpro.2021.12.5.7

Ejemplares similares